AEON Biopharma Posts Q3 Gains with Strong ABP-450 Biosimilarity Data
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
